PI3K inhibitors: review and new strategies

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Phosphoinositide 3-kinase alpha (PI3Kα) signaling is frequently dysregulated in cancer, contributing to tumorigenesis and drug resistance.
• The gene PIK3CA, encoding the p110α catalytic subunit, is highly mutated in various cancers.
• Current FDA-approved and investigational PI3Kα inhibitors are ATP-competitive and can cause severe side effects.

Purpose of the Study:

• To review PI3Kα mutations and the current PI3K drug landscape.
• To propose novel therapeutic strategies for targeting PI3Kα mutants.
• To explore combination therapies and leverage allosteric mutations for drug development.

Main Methods:

• Review of existing literature on PI3Kα mutations and inhibitors.
• Analysis of current PI3Kα drug repertoire, including approved and investigational agents.
• Proposal of novel therapeutic strategies, including combination inhibition and mutation-guided drug discovery.

Main Results:

• PI3Kα mutations are prevalent in cancer, driving aberrant signaling.
• Existing PI3Kα inhibitors face challenges with side effects and resistance.
• Novel therapeutic avenues involving allosteric and orthosteric inhibition are being explored.

Conclusions:

• Targeting PI3Kα is crucial for cancer treatment, but new approaches are needed to overcome limitations of current drugs.
• Combination therapy with allosteric and orthosteric inhibitors offers a promising strategy.
• Exploiting allosteric rescue mutations can guide the development of more effective and specific PI3Kα inhibitors.